> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alembic Pharmaceuticals Recalls 1 Lot of Telmisartan Tablets
- URL: https://www.fdaweb.com/alembic-pharmaceuticals-recalls-1-lot-of-telmisartan-tablets/
- Published: 2021-03-25T12:00:00.000Z
- Updated: 2026-09-14T16:52:23.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148961

Alembic Pharmaceuticals has recalled one lot of telmisartan tablets, USP, 20 mg, packaged in 30-count bottles (Lot # 1905005661) due to a mislabeling concern. The company says it received a complaint that one bottle labeled as 30-count telmisartan tablets 20mg incorrectly contained 30 tablets of telmisartan tablets 40mg. Patients who wrongly received a doubled dose of telmisartan for a prolonged period of time could experience low blood pressure, worsening kidney function, or elevated potassium, which can be life-threatening, according to the [recall notice](https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/alembic-pharmaceuticals-limited-issues-voluntary-nationwide-recall-telmisartan-tablets-usp-20-mg-due?ref=fdaweb.com). The drug is used for treating hypertension.